<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164678">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01688297</url>
  </required_header>
  <id_info>
    <org_study_id>VXA02-001</org_study_id>
    <nct_id>NCT01688297</nct_id>
  </id_info>
  <brief_title>Safety Study of an Oral Vaccine to Prevent Seasonal Influenza</brief_title>
  <official_title>A Randomized Phase 1 Double-Blinded Placebo Controlled Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant Administered Orally to Healthy Volunteers Age 18-49 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine
      to prevent seasonal influenza.  Volunteers will receive placebo as part of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Frequency or severity of vaccine related events as measured through reported AEs.</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of humoral immune response to influenza as measured by functional assays</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of cellular immune responses to influenza as measured by functional assays</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Season Influenza</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One or two doses of replication incompetent adenovirus given in a tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablets of the same size and shape as the experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One or two doses of replication incompetent adenovirus given in a tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of replication incompetent adenovirus given in a tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>One or two doses of replication incompetent adenovirus given in a tablet</intervention_name>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
    <other_name>Ad-HA-dsRNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <arm_group_label>Placebo Tablet</arm_group_label>
    <other_name>Placebo Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health as established by medical history, physical examination, and
             laboratory testing at the time of enrollment.

        Exclusion Criteria:

          -  Positive for H1 influenza by HAI.

          -  Has had an influenza vaccine in the past 2 years.

          -  Current history of chronic alcohol consumption and/or illicit and/or recreational
             drug use.

          -  History of any confirmed or suspected immunodeficient or immunosuppressive condition

          -  Positive serology for HIV, HCV, or HBV

          -  Previous serious reactions to vaccination such as anaphylaxis, respiratory problems,
             hives, or abdominal pain.

          -  History of irritable bowel disease or other inflammatory digestive or
             gastrointestinal conditions that could affect the intended distribution of the
             vaccine targeting the mucosa of the small intestine

          -  Use of proton pump inhibitors(Nexium, Prilosec).

          -  Stool sample with occult blood at baseline exam
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Liebowitz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vaxart, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Apinya Vutikullird, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>WCCT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Foster</last_name>
    <email>Erin.Foster@wcct.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WCCT</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>September 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>H1N1</keyword>
  <keyword>flu</keyword>
  <keyword>seasonal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
